Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Feb 13th based on HKEx daily reports.</li>
<li>In the past 7 days, the top 3 companies that repurchased the most shares from the market were Xiaomi (1810 HK), Geely Automobile (175 HK), Kingsoft (3888 HK).</li>
<li>In the past 30 days, the top 3 companies that repurchased the most shares from the market were Zto Express (2057 HK), Xiaomi (1810 HK), Tencent (700 HK).</li>
</ul>


We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Feb 13th based on HKEx daily reports.
In the past 7 days, the top 3 companies that repurchased the most shares from the market were Xiaomi (1810 HK), Geely Automobile (175 HK), Kingsoft (3888 HK).
In the past 30 days, the top 3 companies that repurchased the most shares from the market were Zto Express (2057 HK), Xiaomi (1810 HK), Tencent (700 HK).


Hong Kong Buybacks Weekly (Feb 13th): Xiaomi, Geely Automobile, Kingsoft

<ul>
<li>We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Feb 6th based on HKEx daily reports.</li>
<li>In the past 7 days, the top 3 companies that repurchased the most shares from the market were Zto Express (2057 HK), Xiaomi (1810 HK), Kingsoft (3888 HK).</li>
<li>In the past 30 days, the top 3 companies that repurchased the most shares from the market were Tencent (700 HK), Zto Express (2057 HK), Xiaomi (1810 HK).</li>
</ul>


We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Feb 6th based on HKEx daily reports.
In the past 7 days, the top 3 companies that repurchased the most shares from the market were Zto Express (2057 HK), Xiaomi (1810 HK), Kingsoft (3888 HK).
In the past 30 days, the top 3 companies that repurchased the most shares from the market were Tencent (700 HK), Zto Express (2057 HK), Xiaomi (1810 HK).


Hong Kong Buybacks Weekly (Feb 6th): Zto Express, Xiaomi, Kingsoft

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of January 16th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Tencent, Kuaishou, China Mobile, Xiaomi, CCB, China Life, Meituan, Hua Hong Semiconductor, Hang Seng Bank, Laopu Gold.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of January 16th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Tencent, Kuaishou, China Mobile, Xiaomi, CCB, China Life, Meituan, Hua Hong Semiconductor, Hang Seng Bank, Laopu Gold.


HK Connect Flows Weekly (Jan 16th): Tencent, Kuaishou, China Mobile, Xiaomi, CCB, China Life

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Shanghai Synyi Medical Technology / Equity Capital Markets

Shanghai Synyi Medical Technology (SSMT HK)

<ul>
<li>The evolution from L2-stage solutions to L3/L4-stage solutions is the key to commercialization for Synyi, but higher-level products need to break through stricter regulations and the trust of clinicians/hospitals.</li>
<li>Revenue scale isn’t big (growing at much slower pace than high-quality innovative drugs after 3-5 years of commercialization).This reflect that Synyi’s products haven’t truly received widespread recognition in medical system.</li>
<li>Comparable company is Yidu. Due to higher revenue growth and gross margin, together with the leading position in the industry, we think valuation of Synyi would be higher than Yidu.</li>
</ul>


The evolution from L2-stage solutions to L3/L4-stage solutions is the key to commercialization for Synyi, but higher-level products need to break through stricter regulations and the trust of clinicians/hospitals.
Revenue scale isn’t big (growing at much slower pace than high-quality innovative drugs after 3-5 years of commercialization).This reflect that Synyi’s products haven’t truly received widespread recognition in medical system.
Comparable company is Yidu. Due to higher revenue growth and gross margin, together with the leading position in the industry, we think valuation of Synyi would be higher than Yidu.


Pre-IPO Shanghai Synyi Medical Technology - The Value of Healthcare AI Remains to Be Verified

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of November 28th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Alibaba, Kuaishou, CMB, Tencent, SMIC, Xiaomi.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of November 28th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Alibaba, Kuaishou, CMB, Tencent, SMIC, Xiaomi.


HK Connect Flows Weekly (Nov 28th): Alibaba, Kuaishou, CMB, Tencent, SMIC, Xiaomi

China

Yidu Tech is an investment holding company that provides healthcare solutions built on big data and artificial intelligence (AI) technologies. It focuses on AI-driven healthcare transformation, developing professional, efficient, precise, and accessible AI products and solutions for the healthcare industry. The company was founded in 2014 and is headquartered in Beijing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Yidu Tech (2158 HK)

Hong Kong Buybacks Weekly (Feb 13th): Xiaomi, Geely Automobile, Kingsoft

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Xiaomi (1810 HK),...

Ke Yan, CFA, FRM

Hong Kong Buybacks Weekly (Feb 6th): Zto Express, Xiaomi, Kingsoft

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Zto Express (2057...

Ke Yan, CFA, FRM

HK Connect Flows Weekly (Jan 16th): Tencent, Kuaishou, China Mobile, Xiaomi, CCB, China Life

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent (700 HK), Kuaishou (1024 HK), China Mobile (941...

Ke Yan, CFA, FRM

Pre-IPO Shanghai Synyi Medical Technology - The Value of Healthcare AI Remains to Be Verified

Synyi's path to commercialization hinges on advancing to higher-level solutions, facing challenges with regulations/clinician trust.Valuation may...

Xinyao (Criss) Wang

HK Connect Flows Weekly (Nov 28th): Alibaba, Kuaishou, CMB, Tencent, SMIC, Xiaomi

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, Kuaishou, CMB, Tencent, SMIC, Xiaomi.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Hong Kong Buybacks Weekly (Feb 13th): Xiaomi, Geely Automobile, Kingsoft

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Xiaomi (1810 HK),...

Ke Yan, CFA, FRM

Hong Kong Buybacks Weekly (Feb 6th): Zto Express, Xiaomi, Kingsoft

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Zto Express (2057...

Ke Yan, CFA, FRM

HK Connect Flows Weekly (Jan 16th): Tencent, Kuaishou, China Mobile, Xiaomi, CCB, China Life

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent (700 HK), Kuaishou (1024 HK), China Mobile (941...

Ke Yan, CFA, FRM

Pre-IPO Shanghai Synyi Medical Technology - The Value of Healthcare AI Remains to Be Verified

​Synyi's path to commercialization hinges on advancing to higher-level solutions, facing challenges with regulations/clinician trust.Valuation may...

Xinyao (Criss) Wang

HK Connect Flows Weekly (Nov 28th): Alibaba, Kuaishou, CMB, Tencent, SMIC, Xiaomi

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, Kuaishou, CMB, Tencent, SMIC, Xiaomi.

Ke Yan, CFA, FRM

Synyi's path to commercialization hinges on advancing to higher-level solutions, facing challenges with regulations/clinician trust.Valuation may...